Navidea Biopharma (NAVB) Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis
Go back to Navidea Biopharma (NAVB) Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis| NAVIDEA BIOPHARMACEUTICALS, Inc. (AMEX: NAVB) | Delayed: 0.04 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.04 | 52 Week High | $1.72 | |||
| Open | $0.04 | 52 Week Low | $0.26 | |||
| Day High | $0.04 | P/E | N/A | |||
| Day Low | $0.04 | EPS | $-0.31 | |||
| Volume | 15,041 | |||||
